gloveharicut

gloveharicut | Joined since 2020-06-02

Investing Experience -
Risk Profile -

Followers

0

Following

0

Blog Posts

455

Threads

1,067

Blogs

Threads

Portfolio

Follower

Following

Summary
Total comments
1,067
Past 30 days
0
Past 7 days
0
Today
0

User Comments
News & Blogs

2020-12-28 15:37 | Report Abuse

I have been sharing on my position in vaccine logistic long time ago. It is public record. You can check it on https://klse.i3investor.com/blogs/gloveharicut/blidx.jsp

glove or vaccine... it is my position and sharing. not promoting.

News & Blogs

2020-12-28 15:36 | Report Abuse

Michael Kwok, I am not promoting anything.

I am compiling the information for my reference.

News & Blogs

2020-12-28 15:04 | Report Abuse

If I can place my order now.

4 Big Heaven God GLOVEs - 15% each

Vaccine - KGB, DKSH, Tasco, freight - 10% each

News & Blogs

2020-12-28 11:53 | Report Abuse

Thank you. I will be there

News & Blogs

2020-12-23 12:04 | Report Abuse

Can I participate next year?

Stock

2020-12-23 11:37 | Report Abuse

paperplane, I am holding & buying.

Do you have anymore recommendation for next few months?


paperplane Good company just hold
23/12/2020 11:12 AM

News & Blogs

2020-12-23 11:01 | Report Abuse

Good morning All. I am still holding my remaining glove & using the profit to buy more vaccine logistics

anyone have good idea to make more money in next few months?
Is recovery theme over play?
Is glove still better stock with clear profit guidance ?

Stock

2020-12-15 15:23 | Report Abuse

Freight management AGM says they are doing cold chain and pharma.

paperplane. Does RM1 taken in the vaccine demand ?

paperplane Rm1 seems no more issue
05/12/2020 9:43 PM

Stock

2020-12-15 11:37 | Report Abuse

TA Securities also said in a recent report that despite encouraging vaccine developments, it reiterated its "overweight" stance on the rubber glove sector.

“We remain bullish as we believe supernormal earnings are here to stay in 2021 and 2022; vaccines will cause a surge in personal protective equipment (PPE) usage, and demand will outstrip supply over the next two years,” it said.

Its top picks are Hartalega (TP: RM25.97) and Kossan (TP: RM9.45), whose average selling prices (ASPs) would be raised more aggressively than peers as the latter play catch-up.

“Also, these companies are direct beneficiaries of increasing daily [new] Covid-19 cases and exceptionally high glove demand.

“2021 is a foregone conclusion — that profit will be exceptional and the same order backlog has flowed into 2022 with no indication of ASPs subsiding yet,” it said.

https://klse.i3investor.com/blogs/gloveharicut/2020-12-15-story-h1538220705-GLOVEs_recoup_some_losses_after_yesterday_s_selldown.jsp

Stock

2020-12-15 11:37 | Report Abuse

TA Securities also said in a recent report that despite encouraging vaccine developments, it reiterated its "overweight" stance on the rubber glove sector.

“We remain bullish as we believe supernormal earnings are here to stay in 2021 and 2022; vaccines will cause a surge in personal protective equipment (PPE) usage, and demand will outstrip supply over the next two years,” it said.

Its top picks are Hartalega (TP: RM25.97) and Kossan (TP: RM9.45), whose average selling prices (ASPs) would be raised more aggressively than peers as the latter play catch-up.

“Also, these companies are direct beneficiaries of increasing daily [new] Covid-19 cases and exceptionally high glove demand.

“2021 is a foregone conclusion — that profit will be exceptional and the same order backlog has flowed into 2022 with no indication of ASPs subsiding yet,” it said.

https://klse.i3investor.com/blogs/gloveharicut/2020-12-15-story-h1538220705-GLOVEs_recoup_some_losses_after_yesterday_s_selldown.jsp

Stock

2020-12-15 11:37 | Report Abuse

TA Securities also said in a recent report that despite encouraging vaccine developments, it reiterated its "overweight" stance on the rubber glove sector.

“We remain bullish as we believe supernormal earnings are here to stay in 2021 and 2022; vaccines will cause a surge in personal protective equipment (PPE) usage, and demand will outstrip supply over the next two years,” it said.

Its top picks are Hartalega (TP: RM25.97) and Kossan (TP: RM9.45), whose average selling prices (ASPs) would be raised more aggressively than peers as the latter play catch-up.

“Also, these companies are direct beneficiaries of increasing daily [new] Covid-19 cases and exceptionally high glove demand.

“2021 is a foregone conclusion — that profit will be exceptional and the same order backlog has flowed into 2022 with no indication of ASPs subsiding yet,” it said.

https://klse.i3investor.com/blogs/gloveharicut/2020-12-15-story-h1538220705-GLOVEs_recoup_some_losses_after_yesterday_s_selldown.jsp

Stock

2020-12-15 11:37 | Report Abuse

TA Securities also said in a recent report that despite encouraging vaccine developments, it reiterated its "overweight" stance on the rubber glove sector.

“We remain bullish as we believe supernormal earnings are here to stay in 2021 and 2022; vaccines will cause a surge in personal protective equipment (PPE) usage, and demand will outstrip supply over the next two years,” it said.

Its top picks are Hartalega (TP: RM25.97) and Kossan (TP: RM9.45), whose average selling prices (ASPs) would be raised more aggressively than peers as the latter play catch-up.

“Also, these companies are direct beneficiaries of increasing daily [new] Covid-19 cases and exceptionally high glove demand.

“2021 is a foregone conclusion — that profit will be exceptional and the same order backlog has flowed into 2022 with no indication of ASPs subsiding yet,” it said.

https://klse.i3investor.com/blogs/gloveharicut/2020-12-15-story-h1538220705-GLOVEs_recoup_some_losses_after_yesterday_s_selldown.jsp